Skip to main content

Advertisement

SpringerLink
Log in

Prevalence and Importance of Comorbidities in Patients With Heart Failure

  • Epidemiology of Heart Failure (J Butler, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Heart failure (HF), being a disease of the elderly, is associated with several noncardiac comorbidities, defined as chronic conditions coexisting with HF that play an integral role in its development, progression, and response to treatment. These include pulmonary dysfunction, sleep-disordered breathing, renal dysfunction, liver dysfunction, anaemia, thyroid disorders, diabetes mellitus, skeletal myopathy, depression, and cognitive impairment. The noncardiac comorbidity burden is higher and associated with higher non-HF hospitalizations in patients with HF and preserved, as compared with those with HF and reduced, left-ventricular ejection fraction. Since chronic inflammation is a characteristic feature of both HF and the coexisting morbidities, it may play a pivotal role in their development, progression, and interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: A report from the american heart association. Circulation. 2011;123:e18–e209.

    Article  PubMed  Google Scholar 

  2. Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. Heart. 2007;93:665–71.

    Article  PubMed  Google Scholar 

  3. • Triposkiadis F, Starling RC, Boudoulas H, et al. The cardiorenal syndrome in heart failure: Cardiac? Renal? Syndrome? Hear Fail Rev. 2012;17:355–66. Interesting review article emphasizing the bidirectional associations between heart failure and coexisting morbidities and the lack of evidence regarding the presence of the cardiorenal syndrome.

    Article  Google Scholar 

  4. •• Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005. Important study which demonstrated a higher noncardiac comorbidity burden associated with higher non-heart failure (HF) hospitalizations in patients with HF and preserved (n = 2,843) vs. those with HF and depressed (n = 6,599) left ventricular ejection fraction during a 2-year follow-up.

    Article  PubMed  Google Scholar 

  5. Waxman AB. Pulmonary function test abnormalities in pulmonary vascular disease and chronic heart failure. Clinics in Chest Medicine. 2001;22:751–8.

    Article  PubMed  CAS  Google Scholar 

  6. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest. 2004;125:669–82.

    Article  PubMed  Google Scholar 

  7. Mettauer B, Lampert E, Charloux A, et al. Lung membrane diffusing capacity, heart failure, and heart transplantation. Am J Cardiol. 1999;83:62–7.

    Article  PubMed  CAS  Google Scholar 

  8. • Szwejkowski BR, Elder DH, Shearer F, et al. Pulmonary hypertension predicts all-cause mortality in patients with heart failure: A retrospective cohort study. Eur J Hear Fail. 2012;14:162–7. Record linkage study in Tayside, Scotland utilizing the Tayside echocardiogram database (>50,000 echocardiograms).Patients were included in the analysis if they had left ventricular systolic dysfunction, right ventricular systolic pressure (RVSP) measurement, and a loop diuretic prescription (provided not more than 1 year prior to echocardiogram). Pulmonary hypertension predicted all-cause mortality in this heterogeneous group of patients with heart failure with each 5 mmHg rise in RVSP was associated with a 6 % increased risk of death.

    Article  Google Scholar 

  9. Chen Y, Guo H, Xu D, Xu X, et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: Heart failure causes severe lung disease. Hypertension. 2012;59:1170–8.

    Article  PubMed  CAS  Google Scholar 

  10. Haddad F, Kudelko K, Mercier O, et al. Pulmonary hypertension associated with left heart disease: Characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis. 2011;54:154–67.

    Article  PubMed  Google Scholar 

  11. Hefke T, Zittermann A, Fuchs U, et al. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation. Thorac Cardiovasc Surg. 2012;60:26–34.

    Article  PubMed  CAS  Google Scholar 

  12. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Hear Fail. 2009;11:130–9.

    Article  Google Scholar 

  13. • Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Hear Fail. 2010;12:1339–44. This study demonstrated in 184 patients with coexistent heart failure (HF) and chronic obstructive pulmonary disease that cardiovascular and pulmonary event-free survival of HF with preserved left ventricular ejection fraction (LVEF) is similar to that of HF with depressed LVEF over 3 years follow-up.

    Article  Google Scholar 

  14. Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. Journal of Thoracic Disease. 2012;4:310–5.

    PubMed  CAS  Google Scholar 

  15. White DP. Pathogenesis of obstructive and central sleep apnoea. Am J Respir Crit Care Med. 2005;172:1363–70.

    Article  PubMed  Google Scholar 

  16. Kasai T, Bradley TD. Obstructive sleep apnoea and heart failure: Pathophysiologic and therapeutic implications. J Am Coll Cardiol. 2011;57:119–27.

    Article  PubMed  Google Scholar 

  17. Bradley TD, Floras JS. Sleep apnoea and heart failure: Part ii: Central sleep apnoea. Circulation. 2003;107:1822–6.

    Article  PubMed  Google Scholar 

  18. • Khayat R, Abraham W, Patt B, et al. Central sleep apnoea is a predictor of cardiac readmission in hospitalized patients with systolic heart failure. J Card Fail. 2012;18:534–40. Prospective observational cohort study of hospitalized patients with systolic heart failure (n = 784) evaluating the impact of sleep disordered breathing on cardiac readmissions. It demonstrated that central sleep apnoea (CSA) is an independent risk factor for 6 months’ cardiac readmissions and that effect size of CSA exceeds that of all known predictors of heart failure readmissions.

    Article  PubMed  Google Scholar 

  19. •• Bitter T, Westerheide N, Prinz C, et al. Cheyne-stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Hear J. 2011;32:61–74. Large-scale long-term study including 472 patients with congestive heart failure after implantation of a cardiac resynchronization device with cardioverter-defibrillator. It demonstrated an association between obstructive sleep apnoea and/or central sleep apnoea and risk for malignant cardiac arrhythmia.

    Article  Google Scholar 

  20. Momomura S. Treatment of Cheyne-Stokes respiration-central sleep apnoea in patients with heart failure. J Cardiol. 2012;59:110–6.

    Article  PubMed  Google Scholar 

  21. • Sharma BK, Bakker JP, McSharry DG, et al.: Adaptive servo-ventilation for treatment of sleep-disordered breathing in heart failure: A systematic review and meta-analysis. Chest. 2012 Jun 21. [Epub ahead of print]. A systematic search including 14 studies (n = 538) which demonstrated that adaptive servo-ventilation (ASV) in adult patients with heart failure and sleep disordered breathing reduces the apnoea/hypopnoea index and improves cardiac function and exercise capacity, providing a rationale for large-scale randomized controlled trials to assess the clinical impact of ASV on hard outcomes in these patients.

  22. Udani SM, Koyner JL. The effects of heart failure on renal function. Cardiol Clin. 2010;28:453–65.

    Article  PubMed  Google Scholar 

  23. • El Nahas M. Cardio-Kidney-Damage: a unifying concept. Kidney Int. 2010;78:14–8. A rational theory which claims that the high prevalence of heart failure and chronic kidney disease in the elderly population is likely to reflect the underlying high prevalence of overt and subclinical atherosclerosis and cardiovascular disease.

    Article  PubMed  Google Scholar 

  24. • Zoccali C, Goldsmith D, Agarwal R, et al. The complexity of the cardio–renal link: taxonomy, syndromes, and diseases. Kidney International Supplements. 2011;1:2–5. Review article emphasizing the lack of evidence regarding the presence of the cardiorenal syndrome.

    Article  Google Scholar 

  25. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–96.

    Article  PubMed  Google Scholar 

  26. Gardner RS, Chong KS, O’Meara E, et al. Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. Eur Hear J. 2007;28:3027–33.

    Article  Google Scholar 

  27. Giamouzis G, Butler J, Triposkiadis F. Renal function in advanced heart failure. Congestive Heart Failure. 2011;17:180–8.

    Article  PubMed  CAS  Google Scholar 

  28. • Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the dopamine in acute decompensated heart failure (DAD-HF) trial. J Card Fail. 2010;16:922–30. Small study in patients with acutely decompensated heart failure which demostrated that the combination of low-dose furosemide and low-dose dopamine (5 μg kg -1  min -1 continuous infusion for 8 hours) is equally effective as high-dose furosemide but associated with improved renal function profile and potassium homeostasis.

    Article  PubMed  CAS  Google Scholar 

  29. Jokinen JJ, Tikkanen J, Kukkonen S, et al. Natural course and risk factors for impaired renal function during the first year after heart transplantation. Journal of Heart and Lung Transplantation. 2010;29:633–40.

    Article  PubMed  Google Scholar 

  30. Odim J, Wheat J, Laks H, et al. Peri-operative renal function and outcome after orthotopic heart transplantation. Journal of Heart and Lung Transplantation. 2006;25:162–6.

    Article  PubMed  Google Scholar 

  31. Benck U, Hoeger S, Brinkkoetter PT, et al. Effects of donor pre-treatment with dopamine on survival after heart transplantation: A cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. J Am Coll Cardiol. 2011;58:1768–77.

    Article  PubMed  CAS  Google Scholar 

  32. Poelzl G, Ess M, Mussner-Seeber C, et al. Liver dysfunction in chronic heart failure: Prevalence, characteristics and prognostic significance. Eur J Clin Investig. 2012;42:153–63.

    Article  CAS  Google Scholar 

  33. Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clinics in Liver Dsease. 2002;6:947–67. viii-ix.

    Article  Google Scholar 

  34. Moller S, Dumcke CW, Krag A. The heart and the liver. Expert Review of Gastroenterology & Hepatology. 2009;3:51–64.

    Article  Google Scholar 

  35. •• Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (charm) program. Eur J Hear Fail. 2009;11:170–7. Evaluation of prevalence and importance of liver function test (LFT) abnormalities in a large (n = 2679) cohort of heart failure patients. Elevated total bilirubin was the strongest LFT predictor of adverse outcome for both the composite outcome of cardiovascular death or heart failure hospitalization and all-cause mortality.

    Article  Google Scholar 

  36. •• Ambrosy AP, Vaduganathan M, Huffman MD, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: An analysis of the EVEREST trial. Eur J Hear Fail. 2012;14:302–11. Post-hoc analysis of the placebo group of the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial including patients hospitalized for systolic heart failure which demonstrated that baseline and in-hospital changes in serum albumin and total billirubin provide additional prognostic value.

    Article  CAS  Google Scholar 

  37. Anand IS. Pathophysiology of anaemia in heart failure. Heart Failure Clinics. 2010;6:279–88.

    Article  PubMed  Google Scholar 

  38. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anaemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101:223–30.

    Article  PubMed  CAS  Google Scholar 

  39. Groenveld HF, Januzzi JL, Damman K, et al. Anaemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818–27.

    Article  PubMed  Google Scholar 

  40. Adams Jr KF, Patterson JH, Oren RM, et al. Prospective assessment of the occurrence of anaemia in patients with heart failure: Results from the study of anaemia in a heart failure population (STAMINA-HFP) registry. Am Hear J. 2009;157:926–32.

    Article  Google Scholar 

  41. Tang YD, Katz SD. Anaemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113:2454–61.

    Article  PubMed  Google Scholar 

  42. Horwich TB, Fonarow GC, Hamilton MA, et al. Anaemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780–6.

    Article  PubMed  Google Scholar 

  43. Le Jemtel TH, Arain S. Mediators of anaemia in chronic heart failure. Heart Failure Clinics. 2010;6:289–93.

    Article  PubMed  Google Scholar 

  44. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al. Hospitalization epidemic in patients with heart failure: Risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail. 2011;17:54–75.

    Article  PubMed  Google Scholar 

  45. Tang WH, Tong W, Jain A, et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anaemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51:569–76.

    Article  PubMed  Google Scholar 

  46. Alexandrakis MG, Tsirakis G. Anaemia in heart failure patients. ISRN Hematology. 2012;2012:246915. Epub 2012 Mar 25.

    Article  PubMed  Google Scholar 

  47. Olivares EL, Carvalho DP. Thyroid hormone metabolism in heart failure: Iodothyronine deiodinases in focus. Current Opinion in Endocrinology, Diabetes, and Obesity. 2010;17:414–7.

    Article  PubMed  CAS  Google Scholar 

  48. Ladenson PW, Sherman SI, Baughman KL, et al. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A. 1992;89:5251–5.

    Article  PubMed  CAS  Google Scholar 

  49. Klein I, Danzi S. Thyroid hormone treatment to mend a broken heart. J Clin Endocrinol Metab. 2008;93:1172–4.

    Article  PubMed  CAS  Google Scholar 

  50. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation. 2010;122:385–93.

    Article  PubMed  Google Scholar 

  51. • Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nature reviews Endocrinology. 2010;6:34–41. Review paper on the pathophyiology identification, and management of amidarone-induced thyroid abnormalities in patients with heart failure.

    Article  PubMed  CAS  Google Scholar 

  52. From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: Prevalence and impact on outcome in the population. Am J Med. 2006;119:591–9.

    Article  PubMed  Google Scholar 

  53. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the acute decompensated heart failure national registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76–84.

    Article  PubMed  Google Scholar 

  54. MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Hear J. 2008;29:1377–85.

    Article  Google Scholar 

  55. Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: Pooled analysis of 39,505 subjects. J Card Fail. 2009;15:305–9.

    Article  PubMed  Google Scholar 

  56. • Al Zadjali MA, Godfrey V, Khan F, et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol. 2009;53:747–53. This study demonstrated in a cohort of 129 consecutive nondiabetic heart failure patients that 61 % suffer from insulin resistance (IR), IR increases significantly with worsening New York Heart Association functional class, and that the presence of IR is associated with a significantly lower exercise capacity and peak oxygen consumption.

    Article  CAS  Google Scholar 

  57. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116:434–48.

    Article  PubMed  CAS  Google Scholar 

  58. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. British Medical Journal. 2007;335(7618):497. Epub 2007 Aug 30.

    Article  PubMed  CAS  Google Scholar 

  59. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–63.

    Article  PubMed  CAS  Google Scholar 

  60. Georgiadou P, Adamopoulos S. Skeletal muscle abnormalities in chronic heart failure. Current Heart Failure Reports. 2012;9:128–32.

    Article  PubMed  Google Scholar 

  61. Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol. 2005;37:1938–47.

    Article  PubMed  CAS  Google Scholar 

  62. von Haehling S, Stepney R, Anker SD. Advances in understanding and treating cardiac cachexia: Highlights from the 5th cachexia conference. Int J Cardiol. 2010;144:347–9.

    Article  Google Scholar 

  63. Duscha BD, Schulze PC, Robbins JL, Forman DE. Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Hear Fail Rev. 2008;13:21–37.

    Article  Google Scholar 

  64. Cicoira M, Zanolla L, Franceschini L, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2001;37:2080–5.

    Article  PubMed  CAS  Google Scholar 

  65. Coats AJ. The “muscle hypothesis” of chronic heart failure. J Mol Cell Cardiol. 1996;28:2255–62.

    Article  PubMed  CAS  Google Scholar 

  66. • Rehn TA, Munkvik M, Lunde PK, et al. Intrinsic skeletal muscle alterations in chronic heart failure patients: A disease-specific myopathy or a result of deconditioning? Hear Fail Rev. 2012;17:421–36. Critical review of the evidence for skeletal muscle alterations in CHF, the underlying mechanisms of such alterations and how skeletal muscle responds to training in this patient group.

    Article  CAS  Google Scholar 

  67. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–37.

    Article  PubMed  Google Scholar 

  68. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.

    Article  PubMed  CAS  Google Scholar 

  69. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–56.

    Article  PubMed  CAS  Google Scholar 

  70. Albert NM, Fonarow GC, Abraham WT, et al. Depression and clinical outcomes in heart failure: An OPTIMIZE-HF analysis. Am J Med. 2009;122:366–73.

    Article  PubMed  Google Scholar 

  71. Freedland KE, Carney RM, Rich MW. Effect of depression on prognosis in heart failure. Heart Failure Clinics. 2011;7:11–21.

    Article  PubMed  Google Scholar 

  72. • O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial. J Am Coll Cardiol. 2010;56:692–9. The SADHART-CHF trial was a randomized, double-blind, placebo-controlled trial of sertraline 50 to 200 mg/day (n = 234) versus matching placebo (n = 235) for 12 weeks in patients with systolic heart failure and clinical depression. Although, sertraline was safe, it did not provide greater reduction in depression or improved cardiovascular status among patients with HF and depression.

    Article  PubMed  Google Scholar 

  73. Dardiotis E, Giamouzis G, Mastrogiannis D, et al. Cognitive impairment in heart failure. Cardiol Res Pract. 2012;2012:595821. Epub 2012 Jun 6.

    PubMed  Google Scholar 

  74. Vogels RL, Oosterman JM, van Harten B, et al. Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc. 2007;55:1764–70.

    Article  PubMed  Google Scholar 

  75. Trojano L. Antonelli Incalzi R, Acanfora D, et al.: Cognitive impairment: A key feature of congestive heart failure in the elderly. J Neurol. 2003;250:1456–63.

    Article  PubMed  Google Scholar 

  76. Zuccala G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Hear J. 2005;26:226–33.

    Article  CAS  Google Scholar 

  77. Kalogeropoulos AP, Georgiopoulou VV, Butler J. From risk factors to structural heart disease: The role of inflammation. Heart Failure Clinics. 2012;8:113–23.

    Article  PubMed  Google Scholar 

  78. Silverstein DM. Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24:1445–52.

    Article  PubMed  Google Scholar 

  79. Cottone S, Lorito MC, Riccobene R, et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. Journal of Nephrology. 2008;21:175–9.

    PubMed  Google Scholar 

  80. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnoea: Overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009;180:692–700.

    Article  PubMed  CAS  Google Scholar 

  81. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnoea syndrome. Circulation. 2005;112:2660–7.

    Article  PubMed  CAS  Google Scholar 

  82. Im SS, Osborne TF. Liver x receptors in atherosclerosis and inflammation. Circ Res. 2011;108:996–1001.

    Article  PubMed  CAS  Google Scholar 

  83. Iredale JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. The Journal of Cclinical Investigation. 2007;117:539–48.

    Article  CAS  Google Scholar 

  84. Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest. 1990;86:1641–8.

    Article  PubMed  CAS  Google Scholar 

  85. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Hear J. 2005;26:2232–7.

    Article  CAS  Google Scholar 

  86. • Kleijn L, Belonje AM, Voors AA, et al.: Inflammation and anaemia in a broad spectrum of patients with heart failure. Heart. 2012 Jun 22. [Epub ahead of print]. Multicentre randomised clinical trial including patients admitted for heart failure (n = 326), which demonstrated that anaemia (Hb <13 g/dl (men) and <12 g/dl (women)) was present in 40 % (130/326) of the study population and that that the levels of IL-6, hsCRP and sTNFR-1 were significantly higher in anaemic than in non-anaemic patients emphasizing the association between anaemia and inflammation.

  87. Garcia C, Feve B, Ferre P, et al. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes & Metabolism. 2010;36:327–38.

    Article  CAS  Google Scholar 

  88. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: From alpha and beta cell compensation to dysfunction. Arch Physiol Biochem. 2009;115:240–7.

    Article  PubMed  CAS  Google Scholar 

  89. Hambrecht R, Adams V, Gielen S, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol. 1999;33:174–9.

    Article  PubMed  CAS  Google Scholar 

  90. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999;33:959–65.

    Article  PubMed  CAS  Google Scholar 

  91. Bartalena L, Bogazzi F, Brogioni S, et al. Role of cytokines in the pathogenesis of the euthyroid sick syndrome. European Journal of Endocrinology / European Federation of Endocrine Societies. 1998;138:603–14.

    Article  PubMed  CAS  Google Scholar 

  92. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med. 1993;329:1246–53.

    Article  PubMed  CAS  Google Scholar 

  93. Krishnadas R, Cavanagh J. Depression: An inflammatory illness? J Neurol Neurosurg Psychiatry. 2012;83:495–502.

    Article  PubMed  Google Scholar 

  94. • Gorelick PB. Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci. 2010;1207:155–62. Review of the observations that have led to the establishment of an association of systemic and brain inflammatory markers on cognitive impairment and dementia.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Cardiology, Larissa University Hospital, Biopolis, Larissa, 41110, Greece

    Filippos K. Triposkiadis & John Skoularigis

Authors
  1. Filippos K. Triposkiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Skoularigis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Filippos K. Triposkiadis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Triposkiadis, F.K., Skoularigis, J. Prevalence and Importance of Comorbidities in Patients With Heart Failure. Curr Heart Fail Rep 9, 354–362 (2012). https://doi.org/10.1007/s11897-012-0110-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-012-0110-z

Keywords

Search

Navigation